BIOAF.US biOasis Technologies Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 14, 2026
0.0001 0.0002
Market cap
USD 7.94K
P/E
-
P/B
53.47x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to May 2023.

Is BIOAF.US undervalued?

Graham number

The Graham number of biOasis Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

biOasis Technologies Inc fundamental analysis

No fundamental analysis for biOasis Technologies Inc yet.

biOasis Technologies Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About biOasis Technologies Inc

Bioasis Technologies Inc. operates as a biopharmaceutical company. The company utilizes its proprietary xB3 platform to deliver therapeutics across the blood-brain barrier and treat central nervous system disorders in areas of high unmet medical need. Bioasis Technologies Inc. is based in New Haven, Connecticut.

Full company profile